Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618940 | 0.81 | BTK (0.39) | KDM1AMMP2ANPEPBTKMAOB | |
| SCHEMBL13618937 | 0.81 | BTK (0.39) | KDM1AMMP2ANPEPBTKMAOB | |
| SCHEMBL12631404 | 0.78 | BTK (0.45) | KDM1ABTKMAOBMAOANFKB1 | |
| SCHEMBL14828632 | 0.77 | BTK (0.43) | KDM1ABTKMAOBMAOANFKB1 | |
| SCHEMBL16676956 | 0.77 | BTK (0.36) | KDM1ABTKMAOBMAOANFKB1 | |
| SCHEMBL14828631 | 0.76 | MMP2 (0.40) | MMP2ANPEP | |
| SCHEMBL16477718 | 0.76 | KDM1A (0.37) | KDM1ABTKMAOBMAOANFKB1 | |
| SCHEMBL13618972 | 0.74 | BTK (0.51) | KDM1ABTKMAOBMAOANFKB1 | |
| SCHEMBL15016060 | 0.74 | BTK (0.51) | KDM1ABTKMAOBMAOANFKB1 | |
| SCHEMBL13696126 | 0.74 | BTK (0.51) | KDM1ABTKMAOBMAOANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | KDM1A 3560/4885MMP2 4212/4885ANPEP 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.